Albert Bourla· @AlbertBourla · X·· 2026-06-08AI 评分27
AI 导读
在新奥尔良举行的#ADASciSessions上，我们的团队分享了我们的主要在研药物的新II期数据，结果支持其成为每月一次治疗的潜力。 患者值得拥有更多选择，我对于能够实现这一点感到乐观。
正文
At the #ADASciSessions in New Orleans, our team shared new Phase 2 data for our lead investigational medicine, with results that support the potential for a once-monthly treatment.
Patients deserve more options, and I am optimistic we can deliver them.
来源：Albert Bourla · x.com